Shawn Singh
President & Chief Executive Officer
Replay available
Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Q4 2025 earnings conference call, held 2025-06-17. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Cindy Anderson
Chief Financial Officer
Andrew Tsai
Analyst, Jefferies
Miles Minter
Analyst, William Blair
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Vistagen Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.073 Good afternoon, everyone, and welcome to Visigyn's 00:00:03.073 -- 00:00:04.914 fiscal year-end 2025 00:00:04.914 -- 00:00:08.016 corporate update conference call and webcast. 00:00:08.016 -- 00:00:13.459 Earlier this afternoon, we issued a press release for our fiscal year-end 2025, 00:00:13.459 -- 00:00:16.841 which ended on March 31st, 2025, 00:00:16.841 -- 00:00:22.344 providing an overview of our progress across our lead clinical stage neuroscience programs. 00:00:22.344 -- 00:00:27.487 We encourage you to review the release and the 10-K, which can be found 00:00:27.487 -- 00:00:31.128 in our website's investor section. 00:00:35.114 -- 00:00:39.615 Before we begin, please note that we make forward-looking statements regarding our business 00:00:39.615 -- 00:00:44.217 during today's call based on current expectations and information. 00:00:44.217 -- 00:00:48.798 These forward-looking statements speak only as of today, except as law requires. 00:00:48.798 -- 00:00:53.800 We do not assume any duty to update any forward-looking statements made today or 00:00:53.800 -- 00:00:58.701 in the future. Of course, forward-looking statements involve risks and uncertainties, 00:00:58.701 -- 00:01:03.683 and our actual results could differ materially from those anticipated by any forward-looking 00:01:03.683 -- 00:01:08.717 statements we may make today. Additional information concerning risks 00:01:08.717 -- 00:01:12.999 and factors that could affect our business and financial results are included in our 00:01:12.999 -- 00:01:15.039 fiscal year-end 2025 00:01:15.039 -- 00:01:16.920 Form 10-K 00:01:16.920 -- 00:01:21.942 for the period ending March 31st, 2025, and in future filings we'll make with the 00:01:21.942 -- 00:01:27.084 SEC from tim...